Joon H Uhm

Dr. Joon H Uhm


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2011 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
JUJoon H Uhm
Joon H Uhm
KBKarla V. Ballman
Karla V. Ballman
WWWenting Wu
Wenting Wu
CGCaterina Giannini
Caterina Giannini
JKJ.C. Krauss
J.C. Krauss
KJKurt A. Jaeckle
Kurt A. Jaeckle

1 April 2019 in Journal of Neurosurgery
Verified
Journal Article
Closed access
BHBenjamin T. Himes
Benjamin T. Himes
MRMichael W. Ruff
Michael W. Ruff
JGJaimie J. Van Gompel
Jaimie J. Van Gompel
SPSean S. Park
Sean S. Park
EGEvanthia Galanis
Evanthia Galanis
JUJoon H Uhm
Joon H Uhm
The authors present the case of a man with a papillary craniopharyngioma, first diagnosed at 47 years of age, who experienced multiple recurrences. Review of the pathologic specimen from his first resection demonstrated the BRAF V600E mutation. With his most recent recurrence following previous surgery and radiotherapy, at 52 years of age, the decision was made to initiate treatment with the BRAF V600E inhibitor dabrafenib. Imaging following initiation of dabrafenib demonstrated reduction in tumor size. He remained on dabrafenib therapy for approximately 1 year and continued to demonstrate a good clinical result. At that time the decision was made to discontinue dabrafenib therapy and follow up with serial imaging. After more than 1 year of follow-up since stopping dabrafenib, the patient has continued to do well with no radiographic evidence of tumor progression and continues to be monitored with frequent interval imaging.

14 May 2012 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
LTL Gerard Toussaint
L Gerard Toussaint
ANAllan E Nilson
Allan E Nilson
JGJennie M Goble
Jennie M Goble
KBKarla V Ballman
Karla V Ballman
CJC David James
C David James
JUJoon H Uhm
Joon H Uhm
High-grade gliomas, including glioblastomas (GBMs), are recalcitrant to local therapy in part because of their ability to invade the normal brain parenchyma surrounding these tumors. Animal models capable of recapitulating glioblastoma invasion may help identify mediators of this aggressive phenotype. Patient-derived glioblastoma lines have been propagated in our laboratories and orthotopically xenografted into the brains of immunocompromized mice. Invasive cells at the tumor periphery were isolated using laser capture microdissection. The mRNA expression profile of these cells was compared to expression at the tumor core, using normal mouse brain to control for host contamination. Galectin-1, a target identified by screening the resulting data, was stably over-expressed in the U87MG cell line. Sub-clones were assayed for attachment, proliferation, migration, invasion, and in vivo tumor phenotype. Expression microarray data identified galectin-1 as the most potent marker (p-value 4.0 x 10-8) to identify GBM cells between tumor-brain interface as compared to the tumor core. Over-expression of galectin-1 enhanced migration and invasion in vitro. In vivo, tumors expressing high galectin-1 levels showed enhanced invasion and decreased host survival. In conclusion, cells at the margin of glioblastoma, in comparison to tumor core cells, have enhanced expression of mediators of invasion. Galectin-1 is likely one such mediator. Previous studies, along with the current one, have proven galectin-1 to be important in the migration and invasion of glioblastoma cells, in GBM neoangiogenesis, and also, potentially, in GBM immune privilege. Targeting this molecule may offer clinical improvement to the current standard of glioblastoma therapy, i.e. radiation, temozolomide, anti-angiogenic therapy, and vaccinotherapy.

1 June 2017 in Mayo Clinic Proceedings
Verified
Journal Article
Closed access
JUJoon H Uhm
Joon H Uhm
APAlyx B. Porter
Alyx B. Porter

1 September 2020 in Clinical Neurology and Neurosurgery
Verified
Journal Article
Closed access
FDFakhry M. Dawoud
Fakhry M. Dawoud
RNRyan M. Naylor
Ryan M. Naylor
CGCaterina Giannini
Caterina Giannini
ASAmy A. Swanson
Amy A. Swanson
FMFredric B. Meyer
Fredric B. Meyer
JUJoon H Uhm
Joon H Uhm

5 July 2024 in Medicine
Verified
Journal Article
Open access
LWLauren Webb
Lauren Webb
MWMason James Webb
Mason James Webb
JCJian L. Campian
Jian L. Campian
SCSamantha J. Pac Caron
Samantha J. Pac Caron
MRMichael W. Ruff
Michael W. Ruff
USUgur Sener
Ugur Sener
Background: Extracranial metastases occur in <2% of cases of glioblastoma (GBM). When metastases do occur, bone is the most common destination. Herein, we review clinical characteristics of GBM patients with osseous metastases and evaluate both potential risk factors and prognostic significance. Methods: Using an institutional database, we identified and retrospectively analyzed 6 patients with both GBM and osseous metastases. We collected data on patient demographics, tumor genetics, clinical courses, and outcomes. Given the rarity of metastatic GBM, we conducted historical comparisons using previously published literature. Results: Five patients with osseous metastases (83%) were male, with a median age of 46 years at GBM diagnosis (range: 20–84). All patients had IDH -wildtype, MGMT promoter unmethylated GBM and 5 (83%) had alterations in TP53 . All patients underwent surgical resection for GBM followed by radiation with concurrent and adjuvant temozolomide. Four patients (67%) received bevacizumab prior to bone metastasis diagnosis. Bone metastases were discovered at a median of 12.2 months (range: 5.3–35.2) after GBM diagnosis and 4.8 months after starting bevacizumab (range: 3.5–13.2). Three patients (50%) received immunotherapy. After osseous metastasis diagnosis, the median survival was 25 days (range: 13–225). Conclusion: In our cohort, most patients were male and young at the time of GBM diagnosis. All patients had IDH -wildtype, MGMT promoter unmethylated GBM, and most had alterations in TP53 , which may be important for osseous metastasis. Most patients received bevacizumab, which has been associated with earlier metastasis. Osseous metastases of GBM occur and portend a dismal prognosis in an already aggressive malignancy.